MT-ND3 and Leigh syndrome: To resolve the genetics underpinning LS in this case we employed a tiered investigation using technologies of increasing resolution that resulted in the identification of a novel mutation in MT-ND3 (m.10134C>A, p.Gln26Lys), which facilitated patient inclusion into the phase 2B clinical trial of EPI-743.